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ABSTRACT
SR proteins and related factors play widespread
roles in alternative pre-mRNA splicing and are
known to promote splice site recognition through
their Arg–Ser-rich effector domains. However,
binding of SR regulators to some targets results in
repression of splice sites through a distinct mech-
anism. Here, we investigate how activated and re-
pressed targets of the Drosophila SR regulator
Transformer2 elicit its differing effects on splicing.
We find that, like activation, repression affects early
steps in the recognition of splice sites and spliceo-
some assembly. Repositioning of regulatory elem-
ents reveals that Tra2 complexes that normally
repress splicing from intronic positions activate
splicing when located in an exon. Protein tethering
experiments demonstrate that this position depend-
ence is an intrinsic property of Tra2 and further
show that repression and activation are mediated
by separate effector domains of this protein. When
other Drosophila SR factors (SF2 and Rbp1) that
activate splicing from exonic positions were tet-
hered intronically they failed to either activate or re-
press splicing. Interestingly, both activities of Tra2
favor the exonic identity of the RNA sequences that
encompass its binding sites. This suggests a model
in which these two opposite functions act in concert
to define both the position and extent of alternatively
spliced exons.
INTRODUCTION
Alternative pre-mRNA splicing is a widespread regulatory
mechanism by which individual genes can express variant
proteins with distinct functions. The selection of
alternative splice sites depends on sequence-speciﬁc asso-
ciation of pre-mRNAs with splicing regulatory factors
that promote or repress their recognition by the
spliceosome. The sites bound by regulators can be
located in either exons or introns and either adjacent to,
or distant from, the affected splice site itself. Interestingly,
number splicing regulators have the ability to either
activate or repress splice sites depending on their target
pre-mRNA (1–6). The position of binding in relation to
the affected splice site is an important factor inﬂuencing
these different effects of splicing regulators. For example
recent transcriptome-wide mapping of RNA-binding sites
of Nova, PTB and Fox2 proteins revealed that binding
within the upstream or downstream intron tends to be
associated with opposite effects on regulated exon
skipping (5,7–9). At present the mechanisms responsible
for such location-speciﬁc effects are in most cases poorly
understood but are likely to involve location-speciﬁc inter-
actions of these factors with the pre-spliceosomal
complexes that are key to splice site recognition.
SR proteins and related splicing factors have important
roles in exon deﬁnition and the regulation of alternative
splicing (10,11).This is exempliﬁed by the production of
alternative mRNAs from Drosophila sex determination
genes. In this system, the splicing of doublesex (dsx) and
fruitless (fru) pre-mRNAs is under the control of the SR-
related regulators Transformer (Tra) and Transformer-2
(Tra2) (12). These factors, along with other SR proteins,
form complexes on exonic splicing enhancers (ESEs) in
these pre-mRNAs that promote the use of sex-speciﬁc al-
ternative splice sites (13–15). Tra2 is a required component
of these enhancer complexes and is able to activate splicing
independently of other SR factors when it is tethered
downstream of a 30-splice site (16,17). More generally,
SR splicing factors activate splice sites when they are
bound to ESEs. Notably, this occurs not only in cases of
alternatively spliced exons but also in many constitutively
spliced exons that depend on activation to prevent exon
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Arg–Ser-rich effector regions characteristic of SR factors.
These domains interact directly with components of
pre-spliceosomal complexes to facilitate their assembly at
the affected splice sites (16,18,19).
In addition to these well-established functions, Tra2 and
other SR factors also repress splicing of some targets
(6,20–25). For example, Tra2 causes retention of the M1
intron in its own pre-mRNA as part of a negative feedback
mechanism that limits its function in vivo (Supplementary
Figure S1) (6,22,26). Repression is mediated by an intronic
splicing silencer (ISS) region with multiple Tra2-binding
sites (27). Both the repression of M1 and the activation of
dsx splicing by Tra2 have been observed to occur together
in the same cells (28) suggesting that cell type-speciﬁc
factors are unlikely to explain the different effects on
splicing in these targets. However, the ESE elements
found in dsx and fru differ from the M1 ISS in both
their exon/intron location and their component sequences
(27) raising the possibility that the composition of regula-
tory complexes, or their positional relationship to affected
splice sites is responsible for the different effects on splic-
ing. Here, we investigate the way in which Tra2–ISS
complexes affect spliceosome assembly and examine the
requirements for their repressive function. Our results
indicate that repression and activation are distinct and
separable effector activities of the Tra2 protein itself and
that its position of binding in the pre-mRNA determines
how target splice sites are affected. We suggest that Tra2,
and perhaps other SR regulators, utilize repression in con-
cert with activation to deﬁne alternatively spliced exons.
MATERIALS AND METHODS
Transcription DNA templates and plasmids
The splicing substrate ftz-ISS contains wild-type (wt) se-
quences from the 78-nt ISS of the M1 intron ﬂanked by ftz
intron and exon sequences. Splicing substrate RNAs from
this plasmid and ftz gene sequences were generated as
described previously (27). To generate dsx-ISS hybrid
splicing substrates lacking the dsx ESE in the female-
speciﬁc exon, a 225-nt EcoRI–XmaI fragment containing
dsx exon 3, intron 3 and 35nt of the female-speciﬁc exon 4
was PCR-ampliﬁed from pdsx (29) and cloned into the
pGEM2 plasmid vector (Promega). An 80-nt XmaI–
XbaI sequence containing the ISS was inserted following
the exon 4 segment to generate pdsx-ISS. An identical
segment in which point mutations converted each of the
ﬁve CAAGR repeats to CTGCT was used to generate
pdsx-5mt.
The dsxMS2 splicing substrate was generated from the
plasmid pdsx70(MS2)2 (17) and contains two high afﬁnity
MS2 coat protein (MCP)-binding sequences separated by
a 15-nt spacer. The same binding sites were used in the
plasmid encoding the ftzM1-MS2 substrate. The MS2 se-
quences were inserted in place of the 78-nt ISS sequence of
pftzM1-208 (27). To generate a series of ftz-MS2 hybrid
RNA substrates, the plasmid pG6V21 (6) which carries
sequences from the wt ftz gene was modiﬁed with two
unique restriction sites (BsiWI and MluI) introduced at
various locations in the intron or 30 exon, A 60-nt
BsiWI–MluI MS2-binding fragment with the same MS2
sequences and spacer as above was then inserted in the
intron either 10 (ftzMS2-10) or 50 (ftzMS2-50) nt upstream
of the branch point or 30-nt downstream (ftzMS2E) of the
30-splice site. The bulged adenosines in these sites required
for MS2 protein binding were deleted by PCR ampliﬁca-
tion from wt MS2-binding sequence with mutagenic pri-
mers. The mutant MS2-binding sequence were inserted
40-nt upstream of the 30-splice site to create the plasmid
ftzMS2-mt. The plasmid pftz30dE was generated by
replacing sequences upstream of the ftz 30-splice site in
pG6V21 with dsx sequences using the same approach.
Construction of the splicing reporter plasmids pActdsxISS
and pActdsxISS-5mt was based on the plasmid pUC18-
ActGFP (Drosophila Genomics Resource Center, DGRC).
The same dsxISS and dsxISS-5mt DNA fragments
described above for production of in vitro splicing sub-
strates were ampliﬁed and inserted into GFP-coding
region in pActGFP. The protein expression plasmid
pAct-Flag-Tra2 was also derived from pActGFP by
replacing GFP cDNA with a 792-bp BamH1–HindIII
fragment of Tra2 cDNA encoding the full-length Tra2
protein and an N-terminal 3X Flag tag.
Protein expression and puriﬁcation
Recombinant His-Tra2 protein corresponding to the
Tra2-PA isoform was prepared using the same methods
described previously (6). To prepare MCP fusion proteins,
Tra2 coding sequences were inserted into the vector
pHis-BIVT-MS2 (30) with BamH1 and HindIII sites.
The MCP-coding sequences in this and all other con-
structs contain point mutations rendering MCP deﬁcient
in formation of capsid oligomers (31). Coding sequences
for Rbp1, and ASF/SF2 and various subsegments of Tra2
were also cloned into pHis-BIVT-MS2 vector. Fusion
protein expression constructs with mutations in the Tra2
RRM domain were recreated by ampliﬁcation of a Tra2
cDNA with outwardly oriented mutagenic primers
followed by insertion into pHis-BIVT-MS2 and complete
resequencing. All MCP fusion proteins were expressed
from baculovirus infected Sf9 cells as described previously
(6). Cells were harvested 3 days after infection and the
proteins were puriﬁed under denaturing conditions on
Ni-NTA agarose and dialyzed against buffer BC850
(20mM Tris–HCl, 850mM KCl, 20% glycerol). The
puriﬁed proteins were stained with coomassie blue after
SDS–PAGE and binding activity was veriﬁed in gel shift
experiments.
In vitro splicing assays
32P-labeled pre-mRNAs were synthesized by using
Megascript T7 kit (Applied Biosystems) after the linear-
ization. The substrates were incubated at 22 C with 50%
Drosophila S2 nuclear extracts or at 30 C with 40% HeLa
nuclear extracts under standard splicing conditions as de-
scribed previously (17,27). Recombinant proteins were
added to the reactions as indicated. The RNA splicing
products and intermediates were separated on 3.5%
denaturing polyacrylamide gels and visualized using
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produced by individual bands were quantitated using
Molecular Dynamics Imagequant software.
Spliceosome assembly assays
32P-labeled RNA was incubated in S2 nuclear extracts
under in vitro splicing conditions. For control reactions
in the absence of ATP, nuclear extracts were depleted of
ATP by incubating at room temperature for 30min. The
20-O-methyl RNA oligonucleotide complementary to U2
small nuclear RNA (U2 snRNA) stem loop (50-CGGUAC
UGCU-30) was added into the reactions to block U2-
branchpoint interaction, while another 20-O-methyl RNA
oligonucleotide complementary to U2 snRNA 50-end (50-C
GAGAAGCGAU-30) was added as a control. Reactions
were terminated by adding heparin to the ﬁnal concentra-
tion of 2mg/ml at the speciﬁed time point and freezing in
liquid nitrogen. Samples were loaded onto a 1.5%
low-melting agarose gel immediately after thawing and
the electrophoresis was conducted at 4 C at 10V/cm for
2.5h (32). Gels were ﬁxed in 50% methanol/15% acidic
acid for 30min before dried at 55 C for 3h.
RNA-binding assays
To verify the RNA-binding competence of various recom-
binant MCP fusion proteins they were incubated with
32P-labeled ftzMS2-10 or ftzMS2mt RNA as described
(16) except that protein–RNA complexes were resolved
by electrophoresis on a 3.5% non-denaturing polyacryl-
amide gel (49:1 bis).
Cell culture and transfections
S2 cells adapted to serum free medium (Dmel2) were
grown at 28 Ci nDrosophila Schneider medium
(Invitrogen) supplemented with 20mM L-glutamine. A
total of 2 10
6 cells were transfected in each well of
six-well plates using the Cellfectin reagent (Invitrogen)
and DNA mixes containing 0.5mg of pActdsxISS-wt or
pActdsxISS-5mt and 1mg of either pActGFP or
pFlagTra2. All plasmids use the Act5C promoter. Cells
were harvested 48h after transfection for RNA extraction.
RNA and protein analysis
Total RNA was extracted from the transfected cells using
the Trizol reagent (Invitrogen) based on the vendor’s in-
structions. After DNase (Promega) treatment, samples
were reverse transcribed using 0.5mg RNA in 20-ml
reaction containing 10U MMLV Reverse Transcriptase
(Roche), 5U RNAase inhibitor (Roche), 2.5mM dNTP
and 10pmol of a downstream primer complementary to
the GFP coding region (50-GAACGCTTCCATCTTCAA
TGTTG-30). Products were then ampliﬁed in presence of
the same downstream primer and 10pmol/l
32P-labeled of
a primer complementary to dsx Exon 3 (50-CCGCTATCC
TTGGGAGCTG-30) and 5U Taq polymerase for
25 cycles. Radiolabeled RT–PCR products were fraction-
ated on 5% non-denaturing polyacrylamide gel. Western
blot were performed using the proteins extracted from the
same transfected cells and the M2 anti-Flag antibody
(Sigma). The results shown are representative of at least
three independent transfections for each of the reporter
genes.
RESULTS
Binding of Tra2 to the ISS inhibits formation of pre-
spliceosomal complexes
The interaction of Tra2 with ESE sequences facilitates
committed pre-spliceosome complex formation and thus
promotes splicing at steps prior to the ﬁrst catalytic
reaction (33). Likewise, Tra2 bound to the ISS is known
to block splicing prior to the ﬁrst catalytic reaction but the
effects it has on spliceosome assembly are not known. To
determine if binding of Tra2 to the ISS inhibits assembly
of pre-spliceosomal complexes, we inserted the intact ISS
into the intron of the fushi-tarazu (ftz) gene and tested
how Tra2 affects its splicing. The ftz intron was chosen
because it has high basal splicing efﬁciency in vitro allowing
the visualization of splicing complexes. In addition,
although the intron is not a normal target of Tra2, it
has been shown previously to undergo Tra2-dependent
repression when ISS sequences are inserted into it (27).
Assembly reactions were ﬁrst carried out on the native
ftz intron in Drosophila Schneider-2 (S2) nuclear extracts
Figure 1. Inhibitory activity of Tra2 in pre-spliceosomal complex
assembly. (A) Spliceosome assembly assays with a fushi tarazu (ftz)
RNA splicing substrate were carried out in Drosophila Schneider 2
(S2) nuclear extract for the times indicated in the presence and
absence of ATP. The positions of ATP-independent complexes (H),
as well as ATP dependent A and C complexes are indicated. (B) Two
20-O-methyl RNA oligos complementary to the U2 small nuclear RNA
(snRNA) are tested for their effects on complex formation in the
presence of ATP. The oligos were targeted at the loop region, essential
for base pairing with the branchsite, and to the non-essential 20nt at
the 50-end of the U2 snRNA. (C) Spliceosomal assembly assays on the
ftz and ftz-ISS substrates were carried out with various amounts of
recombinant Tra2 proteins in the presence of ATP. The dark bar in
the schematic of ftz-ISS indicates the position of the 78-nt ISS element
insertion in the ftz intron as previously described (27).
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shown in Figure 1A, two ATP-dependent low mobility
complexes are observed that are analogous to mammalian
complexes A and C as previously identiﬁed in assembly
reactions carried out in Drosophila extracts (34).
Consistent with this assignment, we found that both of
the complexes depend on the availability of the U2
snRNP loop region that is known to base pair with branch
site sequences in the pre-spliceosome. Incubation of ex-
tracts with a 20-O-methyl oligonucleotide directed at
these pairing sequences inhibited assembly of the both
complexes, while a control oligonucleotide directed at
the 50-end of the U2 snRNP did not (Figure 1B). When
the ISS was inserted into the ftz intron, Tra2 was found to
inhibit assembly of both complexes at protein concentra-
tions that have previously been shown to block forma-
tion of splicing products (Figure 1C) (6). This effect is
due to a speciﬁc interaction with the ISS as Tra2 did not
inhibit complex assembly on the ftz intron alone in paral-
lel controls. These results indicate that Tra2-dependent
complexes bound to the ISS affect pre-spliceosome
assembly in a manner opposite to that which has been
observed for Tra2 dependent complexes formed on the
dsx ESE.
The ISS of the M1 intron activates splicing from an
exonic position
Tra2 dependent ISS and ESE complexes could affect splic-
ing differently due to differences in their composition
or position within the pre-mRNA. To determine if the
ISS can carry out a repressive function from an exonic pos-
ition, we ﬁrst inserted this sequence into the downstream
exon of a dsx minigene construct (ActdsxISS). This
construct lacks the ESE normally present downstream of
the female-speciﬁc 30-splice site as illustrated in Figure 2A.
The plasmid and controls were co-transfected into
Drosophila S2 cells both with and without a plasmid
driving expression of the Tra2 protein with an
N-terminal Flag epitope tag (Flag-Tra2). Although the
ISS has previously been shown to mediate Tra2-dependent
repression of M1 splicing in S2 cells (28), when positioned
exonically the wt ISS caused Tra2-dependent activation of
splicing (Figure 2A). A similar minigene in which each of
the critical CAAGR repeats of the ISS were altered (5mt)
was only slightly activated by Flag-Tra2. These results
show that the ISS is capable of acting as an ESE and
suggest that position is important in determining its
effects on splicing in response to Tra2.
To further examine this issue, we next tested whether
exonic position had a similar effect on ISS function in
Drosophila S2 cell nuclear extracts supplemented with
Tra2 protein. Again a dsx splicing target lacking its ESE
sequence was replaced with either the ISS from the
M1 intron or a version of this sequence with mutant
repeat elements. In vitro splicing reactions were then
carried out in the presence and absence of recombinant
His tagged Tra2 protein. As shown in Figure 2B, Tra2 had
no effect on the substrate with the mutant repeats
(dsx-5mt) but when the ISS with wt repeats (dsx-ISS)
was tested, splicing was activated. Control experiments
with the ISS at an intronic position (ftz-ISS) resulted
in repression as observed previously (27). These experi-
ments show that the ISS can mediate either activation
or repression in nuclear extracts and further supports
the idea that ISS function depends on its position within
the RNA.
Figure 2. ISS acts as an enhancer when positioned in dsx exon. (A) RT–PCR analysis showing enhancer activity of the ISS in transfected S2 cells. A
schematic of splicing reporters dsxISS is shown. The white boxes represent dsx exon 3 and part of the female-speciﬁc exon (F) with the wt dsx intron
sequences between them. The wt ISS or the same sequence with mutations at each of the CAAGR repeats (5mt) was placed 40-nt downstream of
female speciﬁc dsx 30-splice site in the absence of the dsx splicing enhancer. Cells were co-transfected with each reporter construct and a FlagTra2
expression plasmid or pActGFP a control plasmid with the same promoter. RT–PCR was carried out with primers indicated in the diagram by
arrows on total RNA from the co-transfections. Ampliﬁcation products with or without intron retention are indicated. Control RT–PCR products
from Drosophila 18S rRNA gene produced with the same RNA samples are shown. Expression of FlagTra2 was veriﬁed by western blot using
anti-Flag antibody. (B) In vitro splicing assays carried out on constructs in which the ISS (black ﬁlled box) was inserted into either the intron of ftz
or 40-nt downstream of the dsx 30-splice site. Reactions with 0, 100 or 200nM recombinant Tra2 are shown. The positions of unspliced RNA (U),
spliced product (S) and the intron (I) are indicated. The percentage of splicing products and intermediates is indicated below each lane.
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repression
Repression of splicing from intronic positions might
depend on multiple factors that bind to the ISS in com-
bination with Tra2. Alternatively, it is possible that Tra2
binding alone within the M1 intron is sufﬁcient to trigger
repression. We therefore tested how splicing is affected
when Tra2 is tethered within the M1 intron through
fusion to the MS2 coat protein (MCP) in the absence of
ISS sequences. We replaced ISS sequences in an M1-based
splicing substrate ftzM1 (27) with those encoding two
MCP-binding sites and carried out splicing reaction with
this substrate (ftzM1-MS2) in S2 nuclear extracts in the
presence of either the MCP alone or an MCP-Tra2 fusion
protein. The fusion protein binds to speciﬁcally RNA sub-
strates with intact MS2-binding sites (Supplementary
Data S2). However, as shown in Figure 3A, MCP-Tra2
repressed splicing three fold while the MCP protein alone
had no effect. This result suggested that the primary role
of the ISS in repression is to recruit Tra2 and that the
binding of other factors speciﬁed by the ISS is
unnecessary.
Although the ISS is sufﬁcient for Tra2-dependent re-
pression and is deleted from the above substrate, it has
previously been observed that redundant Tra2-binding
sites located within tra2 transcripts but outside the ISS
can mediate modest Tra2-dependent repression of
splicing (6,27). Therefore, we next asked whether
MCP-Tra2 could repress splicing in the context of a sub-
strate based entirely on sequences from the ftz gene in
which splicing is not normally regulated by Tra2.
MCP-binding sites were inserted into the ftz intron at a
position 10-nt upstream of the branch site which is similar
to the position of the ISS in the M1 intron (ftzMS2-10). As
shown in Figures 3B, the MCP–Tra2 protein signiﬁcantly
repressed splicing of this substrate while neither MCP nor
the Tra2 protein alone did so. The same fusion protein did
not affect splicing of a ftz substrate with mutant
MCP-binding sites (ftzMS2-10mt). These results indicate
that the observed repression occurs through binding of
MCP and not Tra2 and further shows that the tethering
of Tra2 to an unregulated intron is sufﬁcient to trigger
splicing repression.
Tethered Tra2 protein represses independently of position
in the intron but activates splicing from an exon
In the above experiment, the MCP-Tra2 fusion proteins
were directed to a position just upstream of the branch site
where pre-spliceosomal complexes assemble. However,
previous studies on the ISS indicate that its function is
not dependent on this proximity and that it effectively
mediates repression when relocated to other positions in
the M1 intron. To determine if a tethered Tra2 protein can
cause repression at a distance, we performed parallel
assays in which Tra2 is tethered 10nt (ftzMS2-10) or
50nt (ftzMS2-50) upstream of the branch site. As shown
in Figure 4A MCP-Tra2 repressed splicing to a similar
extent from these positions indicating that close proximity
to the branch site is not required.
Using a similar tethering approach, MCP-Tra2 fusion
proteins have previously been shown to activate splicing
from exonic positions (17), suggesting that exon/intron
position determines whether activation or repression is
observed. However, these previous studies have been
Figure 3. Tethering of Tra2 to an intron is sufﬁcient to initiate splicing repression. (A) Splicing of ftzM1-MS2, in which the ISS of ftzM1 (27) was
replaced by RNA sequences from the bacteriophage MS2 (shown as stem loops) that bind MCP and MCP fusion proteins, are shown. Other intron
sequences upstream of the polypyrimidine tract (dotted line) derive from the M1 intron. The exons and 30-end of the intron derive from ftz. Splicing
was carried out in the presence of S2 nuclear extract (NE) or extracts supplemented with 100 and 300nM MCP or MCP–Tra2 fusion protein. The
mobilities of in vitro splicing products and the percentage of splicing are indicated as in Figure 2. (B) Shown are splicing reactions carried out on
substrates in which two wt MCP-binding sites (ftzMS2-10), or mutant sites (ftzMS2-mt) were inserted into the intron of the ftz gene. In contrast to
ftzM1, these splicing substrates lack any tra2 RNA sequences. Nuclear extracts (NE) were supplemented with 500nM Tra2 or with 100, 200 or
400nM MCP or MCP-Tra2 protein. The positions of unspliced RNA (U), spliced product (S) and spliced intron (I) are indicated. The percentage of
total signal from splice products and intermediates is indicated below each lane.
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HeLa cells. Thus, it is possible that the difference in
activity observed is due to a difference in experimental
systems and not position of binding. In Figure 4B, we
show that Drosophila S2 nuclear extracts support activa-
tion of splicing when MCP-Tra2 was tethered downstream
of the dsx 30-splice site as was previously reported in HeLa
nuclear extracts.
To determine whether splicing of the ftz substrate was
also activated by Tra2 bound at an exonic position, we
directed MCP-Tra2 to a pair of binding MS2 sites in the
exon immediately downstream of the ftz intron
(ftzMS2E). MCP-Tra2 had little or no effect on splicing
when tethered at this position (Figure 5A). However,
unlike other substrates that have been tested for activation
by tethered SR factors, a majority of the ftz RNA is
spliced even in the absence of tethered protein and it is
unclear if the residual unspliced molecules are available as
splicing reactions do not usually go to completion in vitro.
We therefore hypothesized that poor activation of ftz
splicing could be due to the rather efﬁcient basal splicing
of the ftz intron in vitro. To address this issue, we reduced
the substrate’s basal splicing efﬁciency by substituting a
weak polypyrimidine tract of dsx for that of the ftz
30-splice site (Figure 5B). This resulted in little or no
splicing of the intron in S2 nuclear extracts in the
absence of recombinant protein and, as hypothesized, sig-
niﬁcant activation of splicing upon the addition of
MCP-Tra2 (Figure 5C). Consistent with these observa-
tions, when splicing reactions were carried out in HeLa
nuclear extracts, we observed that the fusion protein trig-
gered activation of splicing by ftzMS2E and repression of
ftzMS2-10 (Supplementary Data S3). These results
support the above conclusions from ﬂy extracts and
further indicate that tethering of Tra2 to the RNA is suf-
ﬁcient to trigger activation or repression that is dependent
on exon/intron position.
MCP-Rbp1 and MCP-SF2 fusion proteins neither activate
nor repress when tethered intronically
We next examined whether the ability to initiate splicing
repression when tethered at an intronic position is shared
Figure 4. Dependence of tethered Tra2 function on binding position. Splicing of RNAs with MCP-binding sequences at different positions are
compared. S2 nuclear extracts were supplemented with 100 or 400nM of Tra2, MCP or MCP-Tra2 as indicated. The mobility of precursors and
products are indicated to the side of each gel as in other ﬁgures. The percentage of total signal from splice products and intermediates is indicated
below each lane. The positions of unspliced RNA (U), spliced product (S) and spliced intron (I) are indicated. (A) Two MS2-binding site inserted
either 50-nt (ftzMS2-50) or 10-nt (ftzMS2-10) upstream of the branch site are tested for the effect of MCP-Tra2. (B) Two MS2 sites were inserted
40-nt downstream of the dsx female-speciﬁc 30-splice site in the absence of the dsx splicing enhancer.
Figure 5. Effects of Tra2 when tethered in the ftz exon. Splicing assays
in S2 extracts with MCP and MCP-Tra2 performed on substrates con-
taining two MS2-binding sites 30-nt downstream of the ftz 30-splice site
are shown. The positions of unspliced RNA (U), spliced product (S)
and spliced intron (I) are indicated. (A) Splicing of ftzMS2E with the
native ftz 30-splice site. Amount of recombinant Tra2 proteins is as in
previous ﬁgures. Note the high-level splicing observed in nuclear extract
alone (NE). The percentage of total signal from splice products and
intermediates is indicated below each lane. (B) Sequences near the ftz
and dsx 30-splice site illustrating the poor pyrimidine content of the
latter. The dsx sequences substituted into the ftz intron in the
modiﬁed substrate (ftz/dsx30) are underlined. (C) Results of in vitro
splicing in S2 nuclear extracts using ftz/dsx30 with 400nM MCP or
100, 200 and 400nM Tra2.
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and repression of splicing (15,21,27,35). MCP fusions were
generated with two such Drosophila SR proteins (Rbp1
and SF2). As shown in Figure 6, these fusion proteins
were able to activate splicing of dsxMS2 consistent with
previous studies on tethered SR factors. Tethering of these
factors to intronic positions in ftzMS2-10 did not increase
splicing indicating that, like Tra2, they depend on exonic
position for their activation function. However, in
contrast to Tra2, both proteins only slightly repressed
splicing from the intronic position. These results suggest
that the repressive activity of intron-tethered Tra2 is not
shared by all SR splicing factors.
The activator and repressor functions of Tra2 require
different effector sequences
We next tested whether the repression function of Tra2
depends on an effector function of its Arg–Ser-rich
regions are known to be effectors of splicing activation
when Tra2 is bound at exonic locations. To determine if
these sequences or other regions of the protein are effect-
ors of splicing repression, we generated a fusion protein
containing the carboxy-terminal Arg–Ser-rich region of
Tra2 with MCP (MCP-RS2) and assayed its ability to
activate splicing of dsxMS2 and to repress splicing of
ftzMS2-10 in Drosophila extracts. Consistent with
previous studies in HeLa extracts (17), the Arg–Ser se-
quences of Tra2 activated splicing almost as well as a
fusion of the full-length Tra2 protein when tethered to
dsxMS2 exonic positions (Figure 7). However, this
fusion lacked the ability to repress splicing of
ftzMS2-10. The effector activity for repression instead
was mapped in the RRM-linker region of the Tra2
protein. A fusion of these sequences with MCP
(MCP-RRM) repressed splicing of ftzMS2-50 but did
not activate splicing of dsxMS2. To further test the role
of these sequences in repression, we assayed fusions of the
intact Tra2 protein that contain previously studied point
mutations in this region (36). The ability to effect repres-
sion was reduced by a mutation (R138L) that is known to
cause strong loss-of-function for sex determination and
fertility in vivo. This mutation affects a conserved
residue in the RNP1 consensus element of the RRM. In
contrast, two mutations (S173A and S173T) that alter a
highly conserved residue near the RRM-linker junction,
and are known to cause partial loss of function pheno-
types in vivo, had no effect on function of the tethered
protein. Together these results indicate that the effector
regions responsible for repression and activation of
Figure 7. Repression and activation of splicing by Tra2 depend on different effector domains. Diagram of various Tra2–MCP protein fusions tested
for effector function are shown. MCP protein sequences, the Arg–Ser-rich regions (RS1 and RS2) as well as the RRM are denoted by various shades
of gray as indicated. White indicates the linker region. Positions of point mutations are indicated with an asterisk. The amino acid changes of various
point mutations are indicated based on their position in the 264 amino acid Tra2-PA isoform. Results are summarized to the right of the diagrams
from quadruplicate splicing assays in S2 nuclear extracts using either ftzMS2-10 for repression (black bar) or dsxMS2 for activation (gray bar).
Effects on splicing are expressed as the average fold activation or repression of splicing observed in each experiment relative to parallel control
splicing reactions supplemented with the MCP protein. A value of 1 indicates no effect from the Tra2 sequences. All reactions were supplemented
with 400nM of the recombinant protein.
Figure 6. Exon and intron tethering of Drosophila SR proteins Rbp1
and ASF/SF2. In vitro splicing reactions with substrates dsxMS2 and
ftzMS2-10 were carried out in S2 nuclear extracts supplemented with
400nM MCP and 100 or 400nM MCP-Tra2, MCP–Rbp1 and MCP–
ASF/SF2 proteins. The positions of unspliced RNA (U), spliced
product (S) and spliced intron (I) are indicated. The percentage of
total signal from splice products and intermediates is indicated below
each lane.
434 Nucleic Acids Research, 2012,Vol. 40,No. 1splicing can be separated and thus are likely to result from
distinct molecular interactions of Tra2.
DISCUSSION
The results presented here indicate that Tra2 has two sep-
arable activities affecting splice site recognition. The
activity observed depends on the position of Tra2-
binding sites in relation to the affected splice site. Splice
sites oriented to remove Tra2-binding sites (intronic orien-
tation) are repressed, while splice sites oriented to include
these binding sites as part of an exon are activated. The
position dependence of these activities would account for
differences previously observed in the effect of Tra2 on its
known targets in Drosophila development.
The mechanism of activation by Tra2 and other SR
factors bound to ESEs has been well studied and results
from the ability of Arg–Ser-rich regions of these proteins
to facilitate assembly of pre-spliceosomal complexes at
splice sites that border the bound exon through inter-
actions with general splicing factors and direct contact
with canonical RNA signals near the splice site (16,19).
Tra2 itself associates with several ESE elements within the
female-speciﬁc exon of the dsx pre-mRNA in combination
with Tra and other SR factors (13,14). While bound at the
ESE these factors cooperate to promote recognition of the
weak female-speciﬁc alternative 30-splice site located
upstream (18,37).
Interestingly, Tra2 and other SR factors can activate
splicing even when they are bound at signiﬁcant distances
from the affected splice sites. For example, the ESE
complexes in dsx RNA are located >290-nt downstream
of the female speciﬁc 30-splice site but are potent activators
switching splicing almost exclusively to this site instead of
a strong downstream 30-splice site (38). Studies on how
distance between ESEs and splice sites affects activation
are consistent with the idea that pre-mRNA acts like a
ﬂexible tether connecting the regulatory complex with
the splice site (30). The amount of splicing observed in
these studies is directly proportional to the calculated ef-
fective concentration of the enhancer complex at the splice
site. RNA looping is thus thought to allow SR factors
bound internally in the exon to interact with pre-
spliceosome complexes.
In its simplest form, this looping model would predict
that Tra2 and other SR factors would also activate splice
sites when bound within an intron over similar distances.
However, as shown here, when Tra2 binds to the ISS
within the M1 intron it prevents pre-spliceosome assembly
and represses the use of the splice sites that ﬂank the
intron. Several Tra2-binding sites in the ISS are located
immediately adjacent to the branch site which is a key sig-
nal in pre-spliceosome formation. In principle, the binding
of Tra2 at this position might inhibit splicing through
direct occlusion of factors that require access to the
branch site. However, experiments in which the ISS was
repositioned farther upstream in the intron yielded equal
levels of repression indicating that the Tra2–ISS com-
plexes can repress splicing at a distance (27). Consistent
with this, we found that tethering of MCP-Tra2 fusion
proteins to positions 10- or 50-nt upstream of the branch-
site, resulted in similar repression. These results suggest
that, like activation, splicing repression can occur at a
distance from the splice site.
It is presently unclear whether the position sensitive re-
pression activity of Tra2 is shared by other Drosophila SR
splicing factors. MCP fusions of both Drosophila SF2 and
Rbp1 activated splicing from exonic positions, but failed
to either repress or activate when bound within the ftz
intron. Thus while exon/intron position appears to be im-
portant for these factors, they do not show the same
ability to repress splicing that Tra2 does. However,
several studies in mammalian systems support the idea
that intronic binding of SR factors leads to repression of
splicing. In the adenovirus late pre-mRNA, it was found
that binding of the human SR protein SRSF1 (formerly
called ASF/SF2) to a series of sites located upstream of
the IIIa 30-splice site leads to repression of that site and
selection of an alternative upstream site (21). As with the
M1 ISS element studied here, the adenovirus elements
functioned from different intronic positions and acted as
splicing enhancer when relocated to an exon (21,39).
Likewise, a repressive role for SR factors was inferred in
studies on RNA substrates derived from the human
b-globin gene (20). Based on a series of in vitro experi-
ments in which the splice sites ﬂanking the middle exon
of a three exon substrate were mutated, it was found that
ESE–SR complexes associated with the disabled exon
acted to repress splicing events between the two outside
exons. In this case the disabled exon is effectively part of
the intron and the ESE acts like an ISS bound by SR
factors. Thus it seems likely that these mammalian SR
factors perform position sensitive repressive functions
similar to those observed of Tra2.
Although the Arg–Ser-rich regions of Tra2 activate
splicing, the effector region responsible splicing repression
maps instead to its RRM domain. Repression is therefore
likely to involve molecular interactions that are distinct
from those involved in splicing activation. The primary
activity ascribed to the single RRM of Tra2 is in binding
of its pre-mRNA target sequences such as those in the ISS
and dsx ESE regions (36,40). In the experiments presented
here, effector function was detected in tethering experi-
ments in which binding is mediated by MCP sequences
and the splicing substrate lack these binding targets.
Effector function therefore is likely to depend on a
second RNA-binding activity of the RRM or its direct
interaction with one or more protein factors. A number
of RRM–protein interactions have now been described
(41) and in some cases RRM domains are known to
interact with RNA and another protein simultaneously
(42,43). Given that Tra2 inhibits splicing complex
assembly, it seems most likely that the Tra2 RRM partici-
pates in a ternary complex that directly interferes with
early steps in the recognition of splice sites.
A number of SR factors are known to preferentially as-
sociate with exonic regions and it has recently been shown
that a variety of hexamer sequences with demonstrated
ESE activity are likewise highly enriched in exonic se-
quences across the transcriptome (44,45). In this regard,
it is interesting that Tra2 promotes exonic identity of its
Nucleic AcidsResearch, 2012, Vol.40,No. 1 435binding sites in both retention of the M1 intron and in-
clusion of alternative exons in dsx and fru splicing. An
attractive idea is that upon binding to multisite regulatory
elements such as these, the activation and repression func-
tions of Tra2, and perhaps other SR factors, act in concert
to deﬁne both the position and the extent of exons in their
target RNAs. The activation function would serve to
ensure that splice sites at the ends of exons are efﬁciently
recognized, while the repressive activity could simultan-
eously inhibit the use of oppositely oriented alternative
or cryptic splice sites that would otherwise excise
internal portions of the exons. The latter activity would
thus ensure the continuity of the exon.
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